Home › Research › Drug development
Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis
Chang YF, Zhang D, Hu WM, Liu DX, Li L.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020-10-14
Topic: Disease mechanisms in lab and animal studies
Background Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue with an extended half-life of approximately 1 week has being come into clinic trial to treat parkingson's disease but little is known about its effect to prevent against Alzheimer's disease (AD). The goal of the present study was to explore the potential mechanisms of semaglutide to protect against AD. Methods We treated SH-SY5Y cell line with Aβ 25-35 as an AD model. Further, SH-SY5Y cells damaged by Aβ 25-35 were treated by semaglutide. Autophagy-related proteins and apoptosis-related proteins were measured to explore molecular mechanisms for semaglutide to protect against Aβ 25-35 . Results Semaglutide enhanced autophagy by increasing the expression of LC3II, Atg7, Beclin-1 and P62 which were inhibited by Aβ 25-35 . Further we showed that semaglutide inhibited apoptosis by inhibiting the expression of Bax induced by Aβ 25-35 and increasing the expression of Bcl2 inhibited by Aβ 25-35 . Conclusion Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ 25-35 .
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chang, Y. F., Zhang, D., Hu, W. M., Liu, D. X., & Li, L. (2020). Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. https://doi.org/10.1016/j.jocn.2020.09.054
Vancouver
Chang YF, Zhang D, Hu WM, Liu DX, Li L. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2020. doi:10.1016/j.jocn.2020.09.054. PMID: 33222922.
BibTeX
@article{chang2020-33222922,
author = {Chang, Y. F. and Zhang, D. and Hu, W. M. and Liu, D. X. and Li, L.},
title = {{Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis}},
journal = {Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia},
year = {2020},
doi = {10.1016/j.jocn.2020.09.054},
pmid = {33222922},
url = {https://doi.org/10.1016/j.jocn.2020.09.054}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Semaglutide enhanced autophagy by increasing the expression of LC3II, Atg7, Beclin-1 and P62 which were inhibited by Aβ 25-35 .
- Further we showed that semaglutide inhibited apoptosis by inhibiting the expression of Bax induced by Aβ 25-35 and increasing the expression of Bcl2 inhibited by Aβ 25-35 .
- Conclusion Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ 25-35 .
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 58 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33222922) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 22 of the 58 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also tagged “glp-1”
285 studies in the library carry the topic tag “glp-1”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.